383 related articles for article (PubMed ID: 28893132)
21. Risk factors and clinical impact of levofloxacin or cefazolin nonsusceptibility or ESBL production among uropathogens in adults with community-onset urinary tract infections.
Wu YH; Chen PL; Hung YP; Ko WC
J Microbiol Immunol Infect; 2014 Jun; 47(3):197-203. PubMed ID: 23063776
[TBL] [Abstract][Full Text] [Related]
22. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
[TBL] [Abstract][Full Text] [Related]
23. Emergence of Extended-Spectrum β-Lactamase Urinary Tract Infections Among Hospitalized Emergency Department Patients in the United States.
Talan DA; Takhar SS; Krishnadasan A; Mower WR; Pallin DJ; Garg M; Femling J; Rothman RE; Moore JC; Jones AE; Lovecchio F; Jui J; Steele MT; Stubbs AM; Chiang WK; Moran GJ
Ann Emerg Med; 2021 Jan; 77(1):32-43. PubMed ID: 33131912
[TBL] [Abstract][Full Text] [Related]
24. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children.
Dalgic N; Sancar M; Bayraktar B; Dincer E; Pelit S
Scand J Infect Dis; 2011 May; 43(5):339-43. PubMed ID: 21271945
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae.
Nakai H; Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Yamagishi Y; Mikamo H
J Infect Chemother; 2016 May; 22(5):319-26. PubMed ID: 26968486
[TBL] [Abstract][Full Text] [Related]
26. What are the risk factors for recurrent UTI with repeated ESBL-producing Enterobacteriaceae? A retrospective cohort study.
Ahn ST; Lee HS; Han DE; Lee DH; Kim JW; Park MG; Park HS; Moon DG; Oh MM
J Infect Chemother; 2023 Jan; 29(1):72-77. PubMed ID: 36195248
[TBL] [Abstract][Full Text] [Related]
27. Clinical profiles of patients colonized or infected with extended-spectrum beta-lactamase producing Enterobacteriaceae isolates: a 20 month retrospective study at a Belgian University Hospital.
Schoevaerdts D; Bogaerts P; Grimmelprez A; de Saint-Hubert M; Delaere B; Jamart J; Swine C; Glupczynski Y
BMC Infect Dis; 2011 Jan; 11():12. PubMed ID: 21226923
[TBL] [Abstract][Full Text] [Related]
28. [Urinary Tract Infections Caused by Community-Acquired Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in a Level III Hospital - A Retrospective Study].
Simões A; Lima M; Brett A; Queiroz C; Chaves C; Oliveira H; Januário L; Rodrigues F
Acta Med Port; 2020 Jul; 33(7-8):466-474. PubMed ID: 31962058
[TBL] [Abstract][Full Text] [Related]
29. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
[TBL] [Abstract][Full Text] [Related]
30. Extended-spectrum beta-lactamase-producing Enterobacteriaceae related urinary tract infection in adult cancer patients: a multicenter retrospective study, 2015-2019.
Wang G; Zhu Y; Feng S; Wei B; Zhang Y; Wang J; Huang S; Qin S; Liu X; Chen B; Cui W
BMC Infect Dis; 2023 Mar; 23(1):129. PubMed ID: 36879210
[TBL] [Abstract][Full Text] [Related]
31. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children.
Fan NC; Chen HH; Chen CL; Ou LS; Lin TY; Tsai MH; Chiu CH
J Microbiol Immunol Infect; 2014 Oct; 47(5):399-405. PubMed ID: 23834784
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Doi A; Shimada T; Harada S; Iwata K; Kamiya T
Int J Infect Dis; 2013 Mar; 17(3):e159-63. PubMed ID: 23140947
[TBL] [Abstract][Full Text] [Related]
33. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
Kim SA; Altshuler J; Paris D; Fedorenko M
Int J Antimicrob Agents; 2018 Jan; 51(1):155-158. PubMed ID: 28943367
[TBL] [Abstract][Full Text] [Related]
34. [Recent evolution of the epidemiological profile of extended-spectrum β-lactamase producing uropathogenic enterobacteria in Marrakech, Morocco].
El Bouamri MC; Arsalane L; Kamouni Y; Berraha M; Zouhair S
Prog Urol; 2014 Jun; 24(7):451-5. PubMed ID: 24861685
[TBL] [Abstract][Full Text] [Related]
35. Urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing and nonproducing bacteria: a comparative study.
Dayan N; Dabbah H; Weissman I; Aga I; Even L; Glikman D
J Pediatr; 2013 Nov; 163(5):1417-21. PubMed ID: 23919903
[TBL] [Abstract][Full Text] [Related]
36. Childhood urinary tract infection caused by extended-spectrum β-lactamase-producing bacteria: Risk factors and empiric therapy.
Uyar Aksu N; Ekinci Z; Dündar D; Baydemir C
Pediatr Int; 2017 Feb; 59(2):176-180. PubMed ID: 27501161
[TBL] [Abstract][Full Text] [Related]
37. Prospective evaluation of colonization with extended-spectrum beta-lactamase (ESBL)-producing enterobacteriaceae among patients at hospital admission and of subsequent colonization with ESBL-producing enterobacteriaceae among patients during hospitalization.
Friedmann R; Raveh D; Zartzer E; Rudensky B; Broide E; Attias D; Yinnon AM
Infect Control Hosp Epidemiol; 2009 Jun; 30(6):534-42. PubMed ID: 19419270
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Bahrain.
Bindayna KM; Senok AC; Jamsheer AE
J Infect Public Health; 2009; 2(3):129-35. PubMed ID: 20701872
[TBL] [Abstract][Full Text] [Related]
39. Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: A French prospective multicenter study.
Madhi F; Jung C; Timsit S; Levy C; Biscardi S; Lorrot M; Grimprel E; Hees L; Craiu I; Galerne A; Dubos F; Cixous E; Hentgen V; Béchet S; ; Bonacorsi S; Cohen R
PLoS One; 2018; 13(1):e0190910. PubMed ID: 29370234
[TBL] [Abstract][Full Text] [Related]
40. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study.
Esteve-Palau E; Solande G; Sánchez F; Sorlí L; Montero M; Güerri R; Villar J; Grau S; Horcajada JP
J Infect; 2015 Dec; 71(6):667-74. PubMed ID: 26380898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
